MedTrace Logo

Effects of Varenicline on Brain Activity During Nicotine Abstinence

NCT00602927 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2011-05-10

Study results available
· View outcomes & findings →

Summary

This project aims to define mechanisms through which varenicline might be an effective smoking cessation medication.

Conditions

  • Nicotine Dependence

Interventions

DRUG

Varenicline

Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - Day 13 1.0mg twice daily

DRUG

Placebo

Participants will take placebo pills for 13 days using the same regimen as the varenicline study period.

Sponsors & Collaborators

Principal Investigators

  • Caryn Lerman, PhD · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00602927 on ClinicalTrials.gov